vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $12.5M, roughly 1.8× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -416.2%, a 417.5% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -0.7%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
NTLA vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $12.5M |
| Net Profit | $-95.8M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -428.9% | 1.5% |
| Net Margin | -416.2% | 1.3% |
| Revenue YoY | 78.8% | -0.7% |
| Net Profit YoY | 25.7% | 129.2% |
| EPS (diluted) | $-0.81 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $12.5M | ||
| Q3 25 | $13.8M | $14.6M | ||
| Q2 25 | $14.2M | $20.4M | ||
| Q1 25 | $16.6M | $14.6M | ||
| Q4 24 | $12.9M | $12.6M | ||
| Q3 24 | $9.1M | $16.9M | ||
| Q2 24 | $7.0M | $13.0M | ||
| Q1 24 | $28.9M | $9.9M |
| Q4 25 | $-95.8M | $163.0K | ||
| Q3 25 | $-101.3M | $-1.1M | ||
| Q2 25 | $-101.3M | $2.7M | ||
| Q1 25 | $-114.3M | $80.0K | ||
| Q4 24 | $-128.9M | $-559.0K | ||
| Q3 24 | $-135.7M | $3.0M | ||
| Q2 24 | $-147.0M | $856.0K | ||
| Q1 24 | $-107.4M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | -428.9% | 1.5% | ||
| Q3 25 | -808.9% | -5.4% | ||
| Q2 25 | -772.2% | 9.4% | ||
| Q1 25 | -726.6% | 1.8% | ||
| Q4 24 | -1059.9% | -1.8% | ||
| Q3 24 | -1589.0% | 19.0% | ||
| Q2 24 | -1998.6% | 8.0% | ||
| Q1 24 | -394.0% | 11.3% |
| Q4 25 | -416.2% | 1.3% | ||
| Q3 25 | -735.2% | -7.7% | ||
| Q2 25 | -710.8% | 13.1% | ||
| Q1 25 | -687.6% | 0.5% | ||
| Q4 24 | -1001.2% | -4.4% | ||
| Q3 24 | -1489.5% | 18.1% | ||
| Q2 24 | -2112.6% | 6.6% | ||
| Q1 24 | -371.3% | 9.0% |
| Q4 25 | $-0.81 | $0.00 | ||
| Q3 25 | $-0.92 | $-0.02 | ||
| Q2 25 | $-0.98 | $0.04 | ||
| Q1 25 | $-1.10 | $0.00 | ||
| Q4 24 | $-1.27 | $0.00 | ||
| Q3 24 | $-1.34 | $0.04 | ||
| Q2 24 | $-1.52 | $0.01 | ||
| Q1 24 | $-1.12 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $17.6M |
| Total Assets | $842.1M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $1.3M | ||
| Q3 25 | $511.0M | $429.0K | ||
| Q2 25 | $459.7M | $4.1M | ||
| Q1 25 | $503.7M | $1.8M | ||
| Q4 24 | $601.5M | $1.4M | ||
| Q3 24 | $658.1M | $2.9M | ||
| Q2 24 | $691.1M | $2.4M | ||
| Q1 24 | $791.3M | $2.0M |
| Q4 25 | $671.4M | $17.6M | ||
| Q3 25 | $748.4M | $17.2M | ||
| Q2 25 | $715.3M | $18.2M | ||
| Q1 25 | $779.9M | $15.2M | ||
| Q4 24 | $872.0M | $14.9M | ||
| Q3 24 | $962.6M | $15.2M | ||
| Q2 24 | $971.1M | $11.9M | ||
| Q1 24 | $1.0B | $5.0M |
| Q4 25 | $842.1M | $50.1M | ||
| Q3 25 | $925.3M | $54.0M | ||
| Q2 25 | $898.9M | $60.0M | ||
| Q1 25 | $986.2M | $57.0M | ||
| Q4 24 | $1.2B | $50.0M | ||
| Q3 24 | $1.2B | $48.0M | ||
| Q2 24 | $1.2B | $40.8M | ||
| Q1 24 | $1.3B | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $1.8M |
| Free Cash FlowOCF − Capex | $-69.4M | — |
| FCF MarginFCF / Revenue | -301.6% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $1.8M | ||
| Q3 25 | $-76.9M | $-2.5M | ||
| Q2 25 | $-99.6M | $-654.0K | ||
| Q1 25 | $-148.9M | $-7.2M | ||
| Q4 24 | $-85.2M | $2.2M | ||
| Q3 24 | $-84.8M | $4.2M | ||
| Q2 24 | $-58.2M | $-565.0K | ||
| Q1 24 | $-120.7M | $-3.9M |
| Q4 25 | $-69.4M | — | ||
| Q3 25 | $-76.9M | — | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-149.7M | — | ||
| Q4 24 | $-86.2M | $-404.0K | ||
| Q3 24 | $-86.1M | $2.8M | ||
| Q2 24 | $-59.2M | $-1.0M | ||
| Q1 24 | $-123.2M | $-3.9M |
| Q4 25 | -301.6% | — | ||
| Q3 25 | -558.2% | — | ||
| Q2 25 | -701.0% | — | ||
| Q1 25 | -900.1% | — | ||
| Q4 24 | -669.4% | -3.2% | ||
| Q3 24 | -945.2% | 16.6% | ||
| Q2 24 | -850.9% | -8.0% | ||
| Q1 24 | -425.7% | -39.9% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 7.6% | 20.6% | ||
| Q3 24 | 14.0% | 8.3% | ||
| Q2 24 | 14.5% | 3.7% | ||
| Q1 24 | 8.7% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SLSN
Segment breakdown not available.
